"NBCC is an organization committed to ending breast cancer in large part by participating in and contributing to the scientific process. The application of drug development science to well-defined problems is an important step in our mission. Therefore, we are pleased to collaborate with BioMarin to develop BMN 673 as a potential first and/or best in class PARP inhibitor for patients with hereditary forms of cancer, namely BRCA mutations. This project offers the hope of improving the length and/or quality of life for patients," said Fran Visco, President of the National Breast Cancer Coalition.
"We look forward to conducting a world-class study, in collaboration with the finest clinical investigators in the world to evaluate the safety and efficacy of BMN 673 in the metastatic setting. Our advocates are poised to change the world through our actions. Ultimately, we hope to prevent women from getting breast cancer and prevent it from spreading outside the breast," Visco added.
"BioMarin is an organization that wants to make big differences in the lives of patients. The data emerging from the ongoing BMN 673 study is progressively more encouraging. We are committed to the successful execution of the Phase 3 program in hopes of offering patients a safe and easily administered pill, which is an effective treatment option," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin. "We are honored to include a seat at the table for our colleagues from NBCC. The purpose of our efforts is best served hearing their voice from the beginning and taking action together."
About the National Breast Cancer Coalition (NBCC)The National Breast Cancer Coalition (NBCC) is dedicated to knowing how to end breast cancer by January 1, 2020 through the power of grassroots action and advocacy. NBCC increases funding for innovative breast cancer research; monitors how those funds are spent; expands access to quality health care for all; and ensures that trained advocates influence all decision making in breast cancer. Join NBCC, learn more and take action visit BreastCancerDeadline2020.org. About Hereditary Breast Cancer with BRCA Mutation BRCA1 and BRCA2 are human genes that belong to a class of genes known as tumor suppressors. Mutation of these genes has been linked to hereditary breast and ovarian cancer. A woman's risk of developing breast and/or ovarian cancer is greatly increased if she inherits a deleterious (harmful) BRCA1 or BRCA2 mutation. Men with these mutations also have an increased risk of breast cancer. Both men and women who have harmful BRCA1 or BRCA2 mutations may be at increased risk of other cancers.